In reply
The recommendations for the management of CAP and surveillance for DRSP were developed by the CDC after obtaining input from clinical and public health experts and members of the DRSP Therapeutic Working Group. We agree with Dr Frothingham that efforts to educate providers and patients about appropriate antimicrobial use for acute bronchitis, rhinitis, pharyngitis, and other viral respiratory infections are a critical element in the effort to control the spread of antimicrobial resistance. Another important principle of judicious antimicrobial use advocates the selection of an agent with the narrowest spectrum effective for the pathogen to be treated.1,2